G-protein coupled receptors (GPCRs) are the largest and most diverse group of membrane receptors in eukaryotes, and detects a wide array of physiological cues in the human body. We describe a new molecular device that couples CRISPR-Cas9 programmed genome regulation to natural and synthetic extracellular signals via GPCRs. The design of our synthetic device, named CRISPR ChaCha, displays superior performance over an architecture proposed by the previously reported Tango system. Using a parsimonious mathematical model and genereporter assays, we find that CRISPR ChaCha can recruit and activate multiple Cas9 molecules for each GPCR molecule. We also characterize key molecular features that modulate CRISPR ChaCha performance. We adopt the design to diverse GPCRs that sense synthetic and natural ligands including chemokines, mitogens, and fatty acids, and observe efficient conversion of signals to customizable genetic programs in mammalian cells, including regulation of endogenous genes. The new class of CRISPR-coupled GPCRs provides a robust and efficient platform for engineering cells with novel behaviors in response to the diverse GPCR ligand repertoire. Eukaryotic cells have evolved diverse classes of transmembrane receptors to transduce various extracellular signals into intracellular responses. Binding of receptors and their cognate ligands triggers their intracellular enzymatic activities. Inside the cell, this leads to complex signaling of downstream signaling protein and secondary messenger functions that ultimately transduce signals to genomic programs. The complexity of these signaling cascades has made it a major challenge to harness natural signaling pathways for cell engineering in a flexible and programmable manner [1]. In the interest of designing rational control over how cells generate behaviors in response to environmental cues, work has been done in cell receptor engineering. Customized cell sensing/response pathways based on synthetic receptors, such as the chimeric antigen receptor (CAR) [2] and the synthetic Notch (synNotch) receptor [3], have been used to engineer T cells to respond to certain disease-relevant signals [4]. These receptors employ antibodybased extracellular domains (e.g., single-chain antibodies or nanobodies), which are limited by the availability of such domains and can only sense cell-surface proteins. Other works developed self-contained receptor-signal transduction systems [5-7].
the ChaCha design with a Dox-inducible adaptor (ARRB2-dCas9-VPR-mCherry) and a constitutively expressed receptor (hM3D-V2-TEVp) (see Methods). Both cell lines use dCas9-VPR or released dCas9-VPR molecules to activate a genomically integrated UAS-driven GFP reporter ( Fig. 1c and Supplementary Fig. 1) .
As shown for the Dox-inducible dCas9-VPR cells (Supplementary Fig. 1) , GFP expression was dependent on the expression levels of dCas9-VPR-mCherry, but not on CNO treatment. A simple DNA-binding model indicated weak power-law dependence of GFP expression to dCas9-VPR levels (power-law exponent n = 0.708, R 2 = 0.95; Supplementary Note 1 and Supplementary Fig. 1a ). This weak power-law dependence corroborates the observed singleturnover activity of Cas9 binding to DNA [24] .
In the CRISPR ChaCha cell line, we modeled GFP expression as a hyperbolic function of both ARRB2-dCas9-VPR-mCherry and CNO ligand concentration, derived from rate equations that parsimoniously described the CRISPR ChaCha process (Box 1). An unbiased non-linear regression fitting of GFP expression in response to varying levels of ARRB2-dCas9-VPR and CNO ( Fig. 1c and Supplementary Note 2) revealed an amplification index, n amp , of 2.33 (R 2 = 0.91). The fitted amplification index for CRISPR ChaCha (n amp > 2) implies that multiple dCas9 effector molecules are released for each ligand-activated receptor. Indeed, setting the n amp to 1 in the model to simulate one dCas9 effector molecule per activated receptor (e.g., Tango architecture) did not recapitulate the strong GFP response measured in our experiments ( Supplementary Fig. 1b ). Our combined experimental measurements and mathematical modeling confirmed that the Chacha design exhibits signal amplification, a feature that is critical for achieving efficient GPCR-mediated responses.
Characterization of design parameters that impact CRISPR ChaCha performance
We characterized various design parameters that modulate the efficiency of CRISPR ChaCha, using hM3D as a model system. These parameters included (1) the linker length between ARRB2, TCS, and dCas9; (2) the proteolytic cleavage efficiency of different TCS sequences; and (3) the expression of hM3D-V2-TEVp via different promoters (Fig. 2) . The original ChaCha design shown in Fig. 1 (designated as variant A) contained a flexible linker of 3 glycine/serine repeats (GSx3) between ARRB2 and TCS. We varied the linker lengths and their locations before or after the TCS (Fig. 2a) . Removing the linker (variant B) led to ~50% reduction of GFP activation upon CNO treatment, suggesting that a flexible linker facilitates hM3D-V2-TEVp access to the TCS. Adding a shorter (variant C, GSx1) or a longer (variant D, GSx5) linker before the TCS restored GFP activation, while introducing a short linker (variant E, GSx1) after the TCS led to leaky basal activation of GFP. The data suggested that proper placement of a flexible linker between ARRB2, TCS, and dCas9 is essential for the efficient ChaCha design.
We then tested how proteolytic cleavage efficiency affects reporter gene activation. We modified the TCS as a spectrum of reported sequences (ENLYFQ/X, where X is any amino acid in variants F -I) [25] (Fig. 2b) . Somewhat surprisingly, we observed that a weaker proteolytic activity achieved the highest dynamic range of the reporter gene (variant A). More efficient proteolytic cleavage dramatically increased the basal activation of the reporter gene in the absence of CNO, and effectively reduced the dynamic range of activation (~2-fold).
We also measured how receptor hM3D-V2-TEVp expression level affected gene activation by using different promoters. The human EF1α (hEF1α) promoter in variant A was replaced with PGK or SFFV promoters (variants J and K) ( Fig. 2c) . While variant J exhibited similar fold activation upon CNO treatment, it also exhibited ~2-fold higher basal activity without CNO.
Interestingly, variant K exhibited the highest dynamic range of activation. Therefore, varying the stoichiometric ratio between receptor and adaptor molecules is an important consideration for optimizing the ChaCha performance in each cell type.
Characterization of kinetics and dose response of CRISPR ChaCha
To characterize the kinetics of gene regulation in the ChaCha system, we tracked GFP activation via live-cell time-lapse microscopy ( Fig. 3a, Supplementary Fig. 2 and Supplementary Movies). We transfected the ChaCha variant K (Fig. 2c) into cells 24 h prior to CNO treatment. We saw that mCherry-tagged ARRB2-TCS-dCas9-VPR proteins were predominantly localized to the cytoplasm during 48 hours of imaging with or without CNO treatment (Supplementary Movies 1 and 2). GFP expression was evident as early as 12 h after addition of CNO ( Supplementary Movies 1 and 3) . In contrast, samples without CNO treatment showed little GFP activation. The observation that gene activation occurs within 12 to 24 h suggests that the ChaCha system can be used to generate fast cell responses to environmental stimuli. We next investigated how gene activation by hM3D-CRISPR ChaCha varied with CNO ligand dose. The dose response curve for hM3D-CRISPR ChaCha displayed a relatively linear behavior, spanning over 2 orders of magnitude of ligand induction ( Fig. 3b, and   Supplementary Fig. 3) . The fitted dose response curve based on the Hill Equation revealed the effective CNO concentration to achieve half-maximal GFP level (EC 50 ) at 105 ± 4 nM (R 2 = 0.95, Fig. 3b ), which is comparable to previously reported EC 50 values using alternative methods [12] .
CRISPR ChaCha promotes efficient activation of endogenous genes
A key advantage of coupling GPCR signaling to the CRISPR-Cas9 system is Cas9's ability to flexibly regulate the mammalian genome in a programmable manner. To demonstrate this ability in the CRISPR ChaCha system, we chose to activate two endogenous genes in HEK293T cells: interleukin 2 (IL2) and Interferon gamma (IFNG), which are cytokine genes that functionally modulate the cell-killing activity of leukocytes. IL2 and IFNG are not actively expressed in HEK293T cells (Supplementary Fig. 4 ).
We designed sgRNAs that efficiently activated each endogenous gene using the dCas9-VPR system and validated them using the appropriate Enzyme-Linked Immunosorbent Assay (ELISA) ( Supplementary Fig. 4 , see Supplementary Methods). We used the most effective sgRNA in combination with the hM3D-CRISPR ChaCha system for ligand-mediated endogenous gene activation. After 48-h CNO treatment, we observed efficient upregulation (3.4-fold for IL2, and 11-fold for IFN-γ) above almost undetectable levels in the absence of ligand ( Fig. 3c,d) . In contrast, the non-targeting sgRNA (sgGal4) showed no response to the CNO ligand for both genes. The data confirmed that the GPCR-coupled CRISPR system could modulate endogenous genes in human cells. The experiment above is also a proof-of-principle application of hM3D-CRISPR ChaCha as an efficient signal converter of a bioinert signal (CNO) into bioactive cytokines (IL2 and IFN-γ).
Expanding the Chacha design to other synthetic GPCRs
We also implemented the ChaCha architecture into another evolved GPCR derived from kappa opioid receptor, KOR-DREADD or KORD, which responds to the ligand, salvinorin B (SALB) [11] ( Fig. 3e) . Like the hM3D ChaCha, the KORD ChaCha exhibited efficient GFP activation (6.4-fold) after 1-day SALB treatment, suggesting that the GPCR component of the ChaCha design is also modular.
Expanding the ChaCha design to natural GPCRs
The G-protein coupled receptor (GPCR) family are the largest and most diverse group of membrane receptors in the human body. We further tested the modularity of the ChaCha design using three natural GPCRs: CXCR4, which senses the chemokine, stromal derived factor 1 (SDF1); NMBR, which senses the mitogen, neuromedin B (NMB); and LPAR1, which senses the fatty acid, lysophosphatidic acid (LPA). All 5 GPCRs (two synthetic and three natural GPCRs) tested here are Class A GPCRs from different branches ( Fig. 4A ). Since structural differences of each natural GPCR likely affect the performance of the ChaCha design, we further tested 3 different variants of fusing TEVp to the C-terminal tail of these natural GPCRs: direct fusion (variant A), partial (variant L) or complete replacement (variant M) ( Supplementary Fig. 4 ).
The ChaCha design worked efficiently for all three tested natural GPCRs, with NMBR exhibiting the best activity ( Fig. 4b) . We further measured the dose-response behavior of NMBR-CRISPR ChaCha. In contrast to the hM3D receptor, the NMBR receptor displayed a narrower induction range ( Fig. 4c, and Supplementary Fig. 6 ). The fitted dose response curve using the Hill Equation revealed an effective NMB concentration to achieve half-maximal GFP level (EC 50 ) at 13 ± 4.2 nM (R 2 = 0.95), comparable to the reported EC 50 values measured using alternative methods (27 nM [26] , or 2 nM [7] ).
We also tested whether natural GPCR-CRISPR ChaCha can efficiently activate endogenous genes. Using the NMBR-CRISPR ChaCha, we observed 20-fold upregulation of the endogenous IFN-γ expression in HEK293T cells after 2-day NMB treatment ( Fig. 4d) . Together, the CRISPR ChaCha system provides an efficient and modular platform that can employ diverse GPCRs for programmable sensing and endogenous gene regulation, which suggests that the strategy is likely generalizable to many other Class A GPCRs.
DISCUSSION
Here we established a novel strategy to couple programmable CRISPR function with the sensing ability of diverse GPCR receptors. We demonstrated this strategy using two synthetic GPCRs and three natural GPCRs. The system is termed as ChaCha, in contrast to the Tango assay, as both depict the interaction between two molecules. In the Tango system, a transcriptional effector (e.g. tTA) is directly fused to the receptor, creating a "one-receptor, oneeffector" system. In contrast, the ChaCha system fuses the transcriptional effector to the adaptor and the protease to the receptor, which turns the receptor into a multi-use enzymatic hub typified in most receptor signaling systems [1, 8] .
The novel CRISPR-coupled GPCR ChaCha system presents several advantages. First, fusing a small protein TEVp to the receptor more likely preserves the conformational fidelity of the GPCR receptor. Our data showed that the hM3D ChaCha is less leaky than hM3D Tango without the CNO ligand (Fig 1b) . Indeed, Tango-ized GPCRs suffer from constitutive activity in the absence of ligands [7] . Second, we show that our ChaCha design amplifies the input signal by possibly recruiting and releasing multiple Cas9 effectors for each receptor, while the Tango design can maximally release one effector per receptor. The rate model (Box 1) allowed quantification of the signal amplification behavior of the ChaCha system. Model fitting into experimental data from hM3D-CRISPR ChaCha suggested that on average 2.33 adaptor-effector molecules (ARRB2-dCas9-VPR) are recruited and released for each activated receptor. Third, the programmability of CRISPR-Cas system allows us to easily redirect the same (synthetic or natural) signal to different synthetic or natural transcriptional outputs (e.g. endogenous IL2 or IFNG). This dramatically expands previous approaches beyond the use of synthetic transcription factors (e.g., GAL4 or tTA) that can only produce synthetic outputs.
GPCRs are a large family of cell-surface receptors that respond to a variety of extracellular signals and which help regulate an incredible range of physiological functions, from sensation to growth to hormone response. Probing GPCR activity in vivo has been a major interest to understand their function [27] . Indeed, ~40% of drugs are developed towards targeting endogenous GPCRs [9] . The ligands detectable by GPCRs include hormones, cytokines, metabolites, small molecule compounds, and signaling peptides. However, the ligands of many orphan GPCRs are difficult to detect or undetectable via antibody-based methods [28] . Among GPCRs with known ligands, how they are dynamically regulated and activated remains a major mystery during development or neural signaling. With the fast kinetics and wider dynamic range of the ChaCha system, we envision that the GPCR research community will be able to more confidently validate novel ligands or drugs as well as profile GPCR signaling and function in vitro and in vivo.
We further envision that the GPCR-coupled CRISPR ChaCha system can be incorporated into diverse cells to create novel cell therapeutic programs. Given the diverse ligand spectrum of 
METHODS
The summary of statistical analyses of all experimental data is included in Supplementary  Table 1 . Standard molecular cloning techniques were performed to assemble all constructs used in this paper and they are included in Supplementary Table 2 .
Generation of genetic constructs
dCas9-effector fusions. Human codon-optimized Streptococcus pyogenes dCas9 was fused at the C-terminus with the tripartite VPR activator [1] . VPR is a fusion of VP64, p65 activation domains, and RTA via two GS linkers. An SV40 nuclear localization signal (NLS) was inserted C-terminal to VP64. For visualization, mCherry was fused at the C-terminus of the construct. The fusion construct was cloned into a pcDNA3 vector with a CMV promoter driving the expression of dCas9-VPR-mCherry. For the rate model, a lentiviral pHR vector with a doxinducible TRE3G promoter was used instead.
Adaptor-dCas9-effector fusions. ARRB2-TCS-dCas9-VPR was assembled by fusing ARRB2 (Human cDNA, NM_004313.3; Origene) with dCas9-VPR-mCherry and clone into a pcDNA3 vector. The TCS sequence ENLYFQ/X was inserted in between and was flanked with GS linkers of varying lengths (Fig. 2) . Two nuclear export signals (NES: LALKLAGLDI) flanked ARRB2 to ensure cytoplasmic localization of the chimera. For the rate model, a lentiviral pHR vector with a dox-inducible TRE3G promoter was used instead.
GPCR-V2-TEVp fusions. Synthetic GPCRs: hM3D (Addgene plasmid #45547) and KORD (Addgene plasmid #65417), natural GPCRs: CXCR4 (Addgene plasmid #66262), NMBR (Addgene #66445), and LPAR1 (Addgene plasmid #66418), and TEV protease (Addgene #8835) were all PCR-amplified and cloned into a pHR lentiviral vector by InFusion (Clontech) cloning. V2 sequence (derived from AVPR2) [2] was inserted in between GPCR and TEVp as primer overhangs via InFusion cloning. For visualization, p2a-BFP was fused C-terminal to TEVp. Expression of GPCR-V2-TEVp-p2a-BFP was driven by an EF1a, PGK or SFFV promoter.
All sgRNAs were cloned into a pHR lentiviral U6-driven expression vector that coexpressed puromycin-p2a-BFP or upstream of the GPCR-V2-TEVp locus for ease of transfection of the three-component GPCR CRISPR ChaCha system. Alternative sgRNA sequences were generated by PCR and inserted by InFusion cloning into the vector digested with BstXI and NotI (New England Biolabs).
Cell culture, lentiviral production and generation of stable cell lines
HEK293T cells (Lenti-X TM , Clontech) were seeded at 5×10 4 /well at day 1 in a 24-well plate format (Corning). At day 2, cells were transfected with the desired plasmids. For each well, 250 ng of each plasmid is mixed in 50 μL of Opti-MEM reduced serum media (Gibco) with 3 μL of Mirus TransIT-LT1 reagent per μg of plasmid added, and then incubated at room temperature for 15-30 minutes. Unless otherwise specified, GPCR ligands were added at the following concentrations at day 3: 20 μM CNO (Cat# C0832, Sigma), 2 μM SALB (Cat# 5611, Tocris), 0.05 μM SDF1 (Cat# 581204, BioLegend), 1 μM NMB (Cat# 1908, Tocris), and 10 μM LPA (Cat# sc-201053, Santa Cruz Biotech).
HEK293T cells were maintained in DMEM High Glucose with GlutaMAX TM media (Thermo Fisher) supplemented with 10% Tet System Approved FBS (Clontech) and 100 U/mL of penicillin and streptomycin (Gibco) at 37 o C with 5% CO 2 . We did not independently authenticate these cell lines and they were not tested for mycoplasma contamination. Filtered lentiviral supernatants were mixed 1:1 with appropriate fresh media to replace media of target cells for transduction. Adherent cell cultures were transduced at 50% confluence. Approximately 10 days after transduction, the HEK293T pTRE3G-EGFP line and the pUAS-EGFP::pEF1a-rtTA-p2a-puro reporter line (pre-selected for 2 days with 1 μg/μL puromycin) were transiently transfected with dCas9-VPR and a targeting sgRNA (sgTET and sgUAS, respectively) for 1 day prior to sorting via EGFP FACS in Carmen (BD InFlux) and Aida (BD Aria II) sorters, respectively. For the rate model, the HEK293T pUAS-GFP line was transduced with pEF1a-hM3D-V2-TEVp-p2a-BFP and pTRE3G-(ARRB2-TCS)-dCas9-VPR-mCherry and sorted approximately 7 days after transduction for both BFP and 1-day doxycycline induction of mCherry expression.
Flow cytometry analysis
Cell were dissociated using 0.05% Trypsin-EDTA (Life Technologies) and analyzed for reporter fluorescence in the Stanford Shared FACS facility with a Scanford FACScan analyzer (Becton Dickinson). For the rate model, cells were filtered into a 96-well plate for high-throughput analysis using the CytoFLEX S flow cytometer (Beckman Coulter).
Time-Lapse Microscopy
At day 0, HEK293T TRE3G-EGFP reporter cells were plated at 1x10 5 cells per 24-well well (μ-Plate 24 well; ibidi). At day 1, 250 ng of each plasmid was transfected (see Fig. 3a and Supplementary Fig. 2) . At day 2, 20 μM of CNO was added to appropriate wells and immediately imaged (Model DMi8, Lumencor SOLA SMII 405, Leica DFC9000; Leica Microsystems) at 37 o C with 5% CO 2 . Leica Application Software was used to set up time-lapse imaging. Images from phase contrast, mCherry and GFP channels were taken every 0.5 h for 48 hours with a 20x/0.40 objective using Leica Adaptive Focus control.
Endogenous Cytokine Activation and Secretion Assays
A day before transfection, HEK293T cells were seeded in 24-well plates at a density of 5x10 4 cells per well. On day 1, cells were transfected with 250 ng of each plasmid (i.e. the CRISPR ChaCha components: GPCR-V2-TEVp of interest, the ARRB2-TCS-dCas9-VPR, and an sgRNA). On day 2, controls were transfected, consisting of the GPCR of interest, dCas9-VPR, and an sgRNA. Media on the ChaCha containing cells was then changed to those with or without ligand treatment (10 μM for CNO; 0.5 μM for NMB).
Supernatants from cell cultures were harvested on day 4, and stored at -80C. Secreted proteins were quantified using the ELISA MAX Deluxe kits for human IL-2 and IFN-γ (BioLegend). Absorbance at 450 nm and 570 nm was measured for samples in technical triplicates with a Synergy H1 plate reader (BioTek). Samples were standardized by subtracting measurements at 570 nm from those at 450 nm. Protein concentrations were then determined by standard curves fitted to a power law using Excel (Microsoft).
Class A GPCR Phylogenetic Tree Construction
The phylogenetic tree in Fig. 4a was constructed using GPCRdb [3, 4] . Human GPCRs from the Swiss-Prot database were used as reference, without any selection for G protein preference. For GPCRs used in this study their entire family was selected, otherwise one GPCR from each family was used to construct the tree. Full-length sequences of receptors were considered for tree construction. No bootstrapping was performed, and distance calculation utilized the neighbor-joining method, utilizing the regular branch lengths option. The tree was then rendered by taking the generated newick file and viewing it in T-REX [5] .
Data Presentation and Analyses
Data are displayed as individual points with sample size indicated in figure legends. No sample size estimates were performed, and the sample sizes used in this study are consistent with those used by similar genome editing and gene regulation studies. Experiments were performed independently at least two times. Values reported are relative to indicated control conditions. No randomization or blinding was performed.
Statistical analysis was performed using SPSS Statistics 21 (version 22, IBM Corporation). Equal variance between populations was not assumed. To account for unequal variance among conditions, Welch's two-sided t-test was performed when comparing two conditions, and Welch's ANOVA was performed followed by Games-Howell post hoc tests when comparing more than two conditions with each other. All statistical data analyses are compiled in Supplementary Table 1 . 
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Supplementary Table 2. Plasmid constructs used in this study listed by figure
ChaCha variants are indicated in parentheses. Constructs used to generate the two reporter cell lines are described in the Methods. 
